Preclinical models show that the PD-1/PD-L1 axis likely contributes to immunosuppression in ASPS, and isolated reports in ASPS patients treated with anti PD-1/PD-L1 agents showed complete responders with a subset of patients remaining disease-free for several years (Groisberg et al., 2017; Conley et al., 2018; Raj et al., 2018; Wilky et al., 2019). This evidence concerns the gene CD274 and alveolar soft part sarcoma.